Form D · Pharmaceuticals
Iterum Therapeutics Bermuda Ltd
Hamilton, D0 · CIK 0001800802
Offering snapshot reported Jan 31, 2020 · SEC filing
- Reported sold
- $51.6M Offering amount: $51.6M
- Investors reported
- 31 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Jan 21, 2020 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Jan 31, 2020 | Initial | $51,588,000 | No comparison | 31 | SEC filing |
Offering details
- Securities
- Debt
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $1.39M
- Finders' fees
- $0
- Form D file number
- Not reported
Sales compensation recipients
Scroll to see all columns →
| Recipient | CRD | Associated broker-dealer |
|---|---|---|
| SVB Leerink LLC | 39011 |
Source: Form D, filed Jan 31, 2020. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No confirmed ADV fund connection is available for this issuer.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Brenton K. Ahrens | Director |
| Louise Barrett | Director |
| Mark Chin | Director |
| Michael Dunne | Executive, Promoter |
| Corey N. Fishman | Director, Executive, Promoter |
| James I. Healy | Director |
| Patrick J. Heron | Director |
| Ronald M. Hunt | Director |
| David Kelly | Director |
| Shahzad Malik | Director |
| Judith M. Matthews | Director |
Issuer details
Industry: Pharmaceuticals (See others in industry)
Address:
Clarendon House 2 Church Street
Hamilton, D0, HM 11
Hamilton, D0, HM 11